Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: | Recruiting |
---|---|
Conditions: | Skin Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/31/2019 |
Start Date: | July 22, 2014 |
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
This randomized phase II trial studies how well dabrafenib and trametinib work in treating
patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf
proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.
patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf
proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES:
I. To compare progression-free survival with intermittent dosing and continuous dosing of
dabrafenib and trametinib among patients with metastatic BRAF V600E/K mutant melanoma.
SECONDARY OBJECTIVES:
I. To estimate the frequency and severity of toxicities of the two dosing schedules.
II. To compare the frequency and severity of fever >= grade 1 per Common Terminology Criteria
for Adverse Events (CTCAE) 4.0 of the two dosing schedules.
III. To compare the response rate (complete and partial response, confirmed and unconfirmed),
overall survival, and survival after progression between the two dosing schedules on step 2.
TRANSLATIONAL MEDICINE OBJECTIVES:
I. To evaluate whether acquired molecular events leading to reactivation of the MAPK pathway
are more common among patients on the continuous dosing arm than on the intermittent dosing
arm using circulating tumor deoxyribonucleic acid (DNA) (ctDNA).
II. To assess the prognostic association between baseline biomarkers and early molecular
events with progression free survival (PFS).
III. To explore the potential interaction between treatment arm and baseline biomarkers/early
molecular events with PFS.
IV. To bank tissue and whole blood in anticipation of future studies to evaluate molecular
events associated with clinical benefit and disease progression in patients treated with
continuous versus intermittent dabrafenib and trametinib.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (CONTINUOUS DOSING): Patients receive dabrafenib orally (PO) twice daily (BID) and
trametinib PO once daily (QD) on days 1-56. Courses repeat every 56 days in the absence of
disease progression or unacceptable toxicity.
ARM II (INTERMITTENT DOSING): Patients receive dabrafenib PO BID and trametinib PO QD on days
1-7 and 29-56. Courses repeat every 56 days in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 3 years and
then yearly for 2 years.
I. To compare progression-free survival with intermittent dosing and continuous dosing of
dabrafenib and trametinib among patients with metastatic BRAF V600E/K mutant melanoma.
SECONDARY OBJECTIVES:
I. To estimate the frequency and severity of toxicities of the two dosing schedules.
II. To compare the frequency and severity of fever >= grade 1 per Common Terminology Criteria
for Adverse Events (CTCAE) 4.0 of the two dosing schedules.
III. To compare the response rate (complete and partial response, confirmed and unconfirmed),
overall survival, and survival after progression between the two dosing schedules on step 2.
TRANSLATIONAL MEDICINE OBJECTIVES:
I. To evaluate whether acquired molecular events leading to reactivation of the MAPK pathway
are more common among patients on the continuous dosing arm than on the intermittent dosing
arm using circulating tumor deoxyribonucleic acid (DNA) (ctDNA).
II. To assess the prognostic association between baseline biomarkers and early molecular
events with progression free survival (PFS).
III. To explore the potential interaction between treatment arm and baseline biomarkers/early
molecular events with PFS.
IV. To bank tissue and whole blood in anticipation of future studies to evaluate molecular
events associated with clinical benefit and disease progression in patients treated with
continuous versus intermittent dabrafenib and trametinib.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (CONTINUOUS DOSING): Patients receive dabrafenib orally (PO) twice daily (BID) and
trametinib PO once daily (QD) on days 1-56. Courses repeat every 56 days in the absence of
disease progression or unacceptable toxicity.
ARM II (INTERMITTENT DOSING): Patients receive dabrafenib PO BID and trametinib PO QD on days
1-7 and 29-56. Courses repeat every 56 days in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 3 years and
then yearly for 2 years.
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed stage IV or unresectable
stage III BRAF V600E or BRAF V600K mutant melanoma
- Patients must have BRAF V600E or BRAF V600K mutation identified by a Clinical
Laboratory Improvement Amendments (CLIA)-certified laboratory; acceptable analytic
techniques include but are not restricted to DNA sequencing, pyrosequencing,
polymerase chain reaction (PCR), melting point assays, and immunohistochemistry
- Contrast-enhanced computed tomography (CT) scans of the neck, chest, abdomen and
pelvis are required; a whole body positron emission tomography (PET)/CT scan with
diagnostic quality images and intravenous iodinated contrast may be used in lieu of a
contrast enhanced CT of the neck, chest, abdomen and pelvis; contrast may be omitted
if the treating investigator believes that exposure to contrast poses an excessive
risk to the patient; patients must have measurable disease per Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1; all measurable lesions must be assessed within
28 days prior to registration; tests to assess non-measurable disease must be
performed within 42 days prior to registration; all disease must be assessed and
documented on the Baseline Tumor Assessment Form (RECIST 1.1)
- Patients must not have received a prior BRAF or mitogen-activated protein kinase
kinase (MEK) inhibitor
- Patients with a history of brain metastases are eligible if the patient is
asymptomatic with no residual neurological dysfunction and has not received
enzyme-reducing anti-epileptic drugs or corticosteroids for at least 7 days prior to
registration
- Patients must not have received any anti-cancer drug within 28 days prior to
registration, and must not have received any nitrosoureas or mitomycin C within 42
days prior to registration
- Patients must not have received any major surgery or immunotherapy within 28 days
prior to registration
- Patients must not have any unresolved toxicity greater than National Cancer Institute
(NCI)-CTCAE version (v) 4.0 grade 1 from previous anti-cancer therapy except alopecia
within 7 days prior to registration
- Absolute neutrophil count (ANC) >= 1,200/ul (obtained within 28 days prior to
registration)
- Platelets >= 100,000/ul (obtained within 28 days prior to registration)
- Hemoglobin >= 9 g/dL (obtained within 28 days prior to registration)
- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (or =< 2.5 x upper
limit of normal [ULN] with Gilbert's syndrome) (obtained within 28 days prior to
registration)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or
< 5 x IULN for patients with known liver metastases) (obtained within 28 days prior to
registration)
- Serum albumin >= 2.5 g/dL (obtained within 28 days prior to registration)
- Serum creatinine =< 1.5 x mg/dL OR measured or calculated creatinine clearance >= 50
mL/min; creatinine measurements must be obtained within 28 days prior to registration
- Patients must have lactate dehydrogenase (LDH) obtained within 28 days prior to
registration in order to obtain baseline stratification information
- Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower
limit of normal (ILLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
within 28 days prior to registration
- Patients must have corrected QT (QTc) =< 480 msec by electrocardiogram (ECG)
(corrected using the Bazett's formula) within 28 days prior to registration
- Patients with known history or current evidence of retinal vein occlusion (RVO) or
central serous retinopathy (CSR) are not eligible:
- History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled
glaucoma or ocular hypertension, uncontrolled systemic disease such as
hypertension, diabetes mellitus, or history of hyperviscosity or
hypercoagulability syndromes)
- Visible retinal pathology as assessed by ophthalmic exam that is considered a
risk factor for RVO or CSR such as:
- Evidence of new optic disc cupping
- Evidence of new visual field defects
- Intraocular pressure > 21 mmHg
- NOTE: ophthalmic exam is required for all patients; exam must be obtained within
28 days prior to registration
- Patients must be able to take oral medications; patients must not have any impairment
of gastrointestinal function or gastrointestinal disease that may significantly alter
the absorption of protocol treatment (e.g. ulcerative disease, uncontrolled nausea,
vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- Patients receiving anticoagulation treatment are allowed to participate with
international normalized ratio (INR) established within the therapeutic range
- Patients must not have a history of pneumonitis or interstitial lung disease
- Patients must not have any grade II/III/IV cardiac disease as defined by the New York
Heart Association criteria (i.e., patients with cardiac disease resulting in marked
limitation of physical activity or resulting in inability to carry on any physical
activity without discomfort), unstable angina pectoris, myocardial infarction within 6
months, or serious uncontrolled cardiac arrhythmia; abnormal cardiac valve morphology
(>= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e.,
mild regurgitation/stenosis]) can be entered on study; patients with a history of
atrial fibrillation must have atrial fibrillation controlled for at least 30 days
prior to registration
- Patients with known hepatitis B or hepatitis C are not eligible, regardless of
concomitant antiretroviral therapy or current viral load
- Patients with known human immunodeficiency virus (HIV) may be eligible providing they
meet the following additional criteria:
- Cluster of differentiation (CD)4 cells >= 500/uL
- Serum HIV viral load of < 25,000 IU/ml
- No current antiretroviral therapy
- Tests must be obtained within 28 days prior to registration; patients who
are HIV positive (+) and do not meet all of these criteria are not eligible
for this study (HIV/hepatitis testing are not required for patients without
known infection)
- Pre-study history and physical must be obtained with 28 days prior to registration
- Patients must have dermatology exam obtained within 28 days prior to registration to
obtain baseline measurement; exam to be performed by treating physician or designated
dermatologist
- Patients must have Zubrod performance status of 0, 1 or 2
- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for three years; exception:
patients with known history of colon cancer, cancer of the pancreas, or any cancer
known to harbor an activating RAS mutation are ineligible regardless of stage or time
since diagnosis
- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures; hormonal contraception is not
allowed
- Patients must be offered the opportunity to participate in specimen banking
- Patients with cutaneous or superficial lesions that do not require imaging guidance
for biopsy must be willing to undergo biopsies for tissue submission and blood draws
for translational medicine
- Patients or their legally authorized representative must be informed of the
investigational nature of this study and must sign and give written informed consent
in accordance with institutional and federal guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system
- STEP 2: RANDOMIZATION
- After completing one cycle of therapy, patients will be registered for randomization
between intermittent and continuous dosing, provided that they were eligible for the
initial step 1 registration and satisfy the following criteria
- Patients must not have unequivocal disease progression (by RECIST v1.1) during the
first cycle; patients must have disease assessed using the same method as baseline
within +/- 5 days of the day 56 scheduled assessment (between days 51-55 of cycle 1,
or days 1-5 of cycle 2); all disease must be assessed and documented on the follow-up
tumor assessment form (RECIST 1.1)
- Patients must be registered to step 2: randomization within +/- 5 days of starting
cycle 2; patients MUST NOT be registered prior to the day 56 disease assessment
We found this trial at
754
sites
1234 West Napier Avenue
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Principal Investigator: Kathleen J. Yost
Phone: 800-865-7884
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Peter Rubin
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Natale T. Sheehan
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Rangaswamy Govindarajan
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: John A. Keech
Phone: 907-458-5380
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-486-6000
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-487-7447
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-678-9000
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-539-2273
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
Altamonte Springs, Florida 32701
Principal Investigator: Carlos A. Alemany
Phone: 888-823-5923
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
American Fork, Utah 84003
Principal Investigator: Brian P. Tudor
Phone: 435-688-4167
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Han A. Koh
Phone: 800-398-3996
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: John E. Doster
Phone: 864-512-4651
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Christopher D. Lao
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Tatjana Kolevska
Phone: 877-642-4691
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 800-506-2550
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 828-213-4150
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Ragini R. Kudchadkar
Phone: 404-778-1868
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 907-458-5380
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Steven R. Schuster
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Yujie Zhao
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 305-674-2625
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
Principal Investigator: John A. Keech
Phone: 907-458-5380
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Han A. Koh
Phone: 800-398-3996
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Mei Tang
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Diwakar Davar
Phone: 412-692-2001
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
118 Northport Avenue
Belfast, Maine 04915
Belfast, Maine 04915
Principal Investigator: Peter Rubin
Phone: 207-338-2500
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 907-458-5380
Click here to add this to my saved trials
Bellevue, Washington 98005
Principal Investigator: Gary E. Goodman
Phone: 206-215-3962
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Han A. Koh
Phone: 800-398-3996
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 541-706-2909
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Christina E. Brzezniak
Phone: 301-319-2100
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
Click here to add this to my saved trials
Click here to add this to my saved trials
Biddeford, Maine 04005
Principal Investigator: Peter Rubin
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Robert M. Conry
Phone: 205-934-0220
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-224-5593
Click here to add this to my saved trials
Bristol, Virginia 24201
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Gary E. Goodman
Phone: 818-847-4793
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Christopher P. Tretter
Phone: 781-744-8027
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Thomas J. Saphner
Phone: 414-302-2304
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials